Fig 5. Neutralizing antibodies against adhesion molecules and a Toll-like receptor (TLR)9 antagonist inhibit leukemic cell adhesion to histone-treated endothelial cells (EA.hy926; hEC).

(A) Histone-treated hEC were treated with neutralizing antibodies against adhesion molecules (50 μg/mL anti-E-selectin, 10 μg/mL anti-ICAM-1, or 30 μg/mL anti-VCAM-1) for 10 min. Then U937 cells were added and incubated for 30 min, and the adherent U937 cells were counted. (B) Antagonists of TLR2 (50 μg/mL), TLR4 (50 μg/mL) and TLR9 (50 μM) were pre-incubated with hEC before histone stimulation and the adhesion assays were then performed. *P < 0.05 versus control; ^#P < 0.05 versus histone-treated.